Kai-Min is a virologist with over a decade of lab experience in molecular and cellular biology assays with a speciality in viral infections. He holds a PhD from the University of Cambridge, where he applied MS proteomics to study immune response against human cytomegalovirus. As a postdoc at Imperial College London, he addressed the adaptive immune response targeting SARS-CoV2. At RQ, Kai-Min develops innovative assays to characterize RQ’s novel antibody discoveries.

Before joining RQ, Kai-Min was part of biology discovery team of Amphista Therapeutics, a Cambridge-based biotech that focuses on targeted protein degradation drug discovery. His work contributed to portfolio expansion and scientific operations during the company’s exponential growth phase.